ArticleJournal of virology2006
Promoter activation by the varicella-zoster virus major transactivator IE62 and the cellular transcription factor USF.
Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Interferon Gamma Inhibits Varicella-Zoster Virus Replication in a Cell Line-Dependent Manner.Journal of virology · 2019Article
- Molecular Aspects of Varicella-Zoster Virus Latency.Viruses · 2018Review
- Analysis of IE62 mutations found in Varicella-Zoster virus vaccine strains for transactivation activity.Journal of microbiology (Seoul, Korea) · 2018Article
- Article
- Functional Characterization of the Serine-Rich Tract of Varicella-Zoster Virus IE62.Journal of virology · 2016Article
- Full trans-activation mediated by the immediate-early protein of equine herpesvirus 1 requires a consensus TATA box, but not its cognate binding sequence.Virus research · 2016Article
- Differential effects of Sp cellular transcription factors on viral promoter activation by varicella-zoster virus (VZV) IE62 protein.Virology · 2015Article
- Cellular transcription factor YY1 mediates the varicella-zoster virus (VZV) IE62 transcriptional activation.Virology · 2014Article
- Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.Virology · 2013Article
- Identification and functional characterization of the Varicella zoster virus ORF11 gene product.Virology · 2011Article
- Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses.Journal of virology · 2010Article
- Role of the IE62 consensus binding site in transactivation by the varicella-zoster virus IE62 protein.Journal of virology · 2010Article
- Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis.Journal of virology · 2009Article
- Varicella-zoster virus IE62 protein utilizes the human mediator complex in promoter activation.Journal of virology · 2008Article
- Cellular transcription factors Sp1 and Sp3 suppress varicella-zoster virus origin-dependent DNA replication.Journal of virology · 2008Article
- Varicella-zoster virus open reading frame 66 protein kinase is required for efficient viral growth in primary human corneal stromal fibroblast cells.Journal of virology · 2008Article
- The ubiquitous cellular transcriptional factor USF targets the varicella-zoster virus open reading frame 10 promoter and determines virulence in human skin xenografts in SCIDhu mice in vivo.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The varicella-zoster virus major transactivator, IE62, can activate expression from homologous and heterologous promoters. High levels of IE62-mediated activation appear to involve synergy with cellular transcription factors. The work presented here focuses on functional interactions of IE62 with the ubiquitously expressed cellular factor USF. We have found that USF can synergize with IE62 to a similar extent on model minimal promoters and the complex native ORF28/29 regulatory element, neither of which contains a consensus IE62 binding site. Using Gal4 fusion constructs, we have found that the activation domain of USF1 is necessary and sufficient for synergistic activation with IE62. We have mapped the regions of USF and IE62 required for direct physical interaction. Deletion of the required region within IE62 does not ablate synergistic activation but does influence its efficiency depending on promoter architecture. Both proteins stabilize/increase binding of TATA binding protein/TFIID to promoter elements. These findings suggest a novel mechanism for the observed synergistic activation which requires neither site-specific IE62 binding to the promoter nor a direct physical interaction with USF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.